| Literature DB >> 29427955 |
Maximus Berger1, Robert-Paul Juster2, Sabine Westphal3, G Paul Amminger4, Bernhard Bogerts5, Kolja Schiltz6, Sabine Bahn7, Johann Steiner8, Zoltan Sarnyai9.
Abstract
Current pathophysiological models of schizophrenia suggest that stress contributes to the etiology and trajectory of the disorder. We investigated if allostatic load (AL), an integrative index of neuroendocrine, immune and metabolic dysregulation in response to chronic stress, is elevated in patients with schizophrenia (SCZ) and first-episode psychosis (FEP) and related to psychotic symptoms and social and occupational functioning. Additionally, we assessed the temporal dynamics of AL in response to treatment with second-generation antipsychotics. AL, psychotic symptoms and psychosocial functioning were assessed in a longitudinal design in patients with SCZ (n = 28), FEP (n = 28), and healthy controls (n = 53) at baseline and 6 and 12 weeks after commencement of antipsychotic therapy. AL at baseline was higher in patients with SCZ and FEP relative to controls, but not different between patients with SCZ and FEP. Adjusting for age and smoking, we found that positive symptoms were positively correlated with AL and psychosocial functioning was negatively correlated with AL at trend level. Linear mixed model analysis demonstrated that AL decreased after treatment was commenced in patients with SCZ and FEP between the baseline assessment and the 6 and 12-week follow-up. AL was not predictive of treatment response or symptomatic remission. Our data provide evidence for cumulative physiological dysregulation in patients with SCZ and FEP that is linked to the experience of current positive psychotic symptoms. AL could be a useful tool to monitor biological signatures related to chronic stress and unhealthy behaviors in schizophrenia.Entities:
Keywords: Allostatic load; Biomarkers; First-episode psychosis; Hpa-axis; Schizophrenia; Treatment outcomes
Mesh:
Substances:
Year: 2018 PMID: 29427955 DOI: 10.1016/j.psyneuen.2018.02.001
Source DB: PubMed Journal: Psychoneuroendocrinology ISSN: 0306-4530 Impact factor: 4.905